Bicara Therapeutics (NASDAQ:BCAX) Stock Gets Price Target Trim from Stifel Nicolaus

Bicara Therapeutics (NASDAQ:BCAX) had its target price lowered by Stifel Nicolaus from $45.00 to $43.00 in a report released on Tuesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

BCAX has been the topic of a number of other reports. Mizuho lifted their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. The Goldman Sachs Group cut Bicara Therapeutics from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $20.00 to $8.00 in a research report on Friday, October 30th. Wells Fargo & Company upped their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Citigroup reaffirmed a “market outperform” rating on shares of Bicara Therapeutics in a research report on Tuesday. Finally, HSBC cut Bicara Therapeutics to an “equal weight” rating in a research note on Tuesday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.33.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock opened at $10.11 on Tuesday. Bicara Therapeutics has a 52 week low of $7.87 and a 52 week high of $30.99. The company’s 50 day moving average price is $17.10 and its two-hundred day moving average price is $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, November 9th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). On average, analysts forecast that Bicara Therapeutics will post -3.82 EPS for the current fiscal year.

Insider Activity

In related news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the sale, the chief executive officer owned 181,641 shares of the company’s stock, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in shares of Bicara Therapeutics by 33.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 44,425 shares of the company’s stock worth $827,000 after acquiring an additional 11,086 shares during the period. Nan Fung Trinity HK Ltd. increased its holdings in Bicara Therapeutics by 49.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 427,885 shares of the company’s stock worth $7,963,000 after acquiring an additional 142,390 shares during the last quarter. Alps Advisors Inc. increased its holdings in Bicara Therapeutics by 32.5% in the 3rd quarter. Alps Advisors Inc. now owns 87,692 shares of the company’s stock worth $1,632,000 after acquiring an additional 21,510 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics in the 3rd quarter valued at about $63,000. Finally, Profund Advisors LLC raised its stake in Bicara Therapeutics by 7.2% in the 3rd quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock valued at $314,000 after acquiring an additional 1,140 shares during the period.

Trending Headlines about Bicara Therapeutics

Here are a few of the latest headlines about BCAX:

• Positive Sentiment: HC Wainwright kept its Buy rating on BCAX and a $36 price target, which could support investor optimism despite the target reduction from $42. HC Wainwright target update
• Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, and BTIG Research issued a pessimistic forecast. These actions may weigh on sentiment; the provided headlines do not specify the revised targets or detailed rationale. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright’s 2027 estimates project continuing quarterly losses, including a full-year loss of $4.63 per share. Expectations of ongoing losses can be a headwind for a clinical-stage biotech, even with the firm’s Buy rating.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.